Bioxodes appears as one of the 150 biotech companies in the “Mapping Rare Disease in 2026” report by Stifel Financial Corp. This comprehensive study is a valuable contribution, which will help raise awareness for diseases such as stroke. “Bioxodes exemplifies using a rare, acute condition to validate a novel therapeutic approach with broad potential,” the report says. “By starting with an orphan disease, Bioxodes aims to de-risk a platform that could address both rare and common conditions.” Stifel is a multinational independent investment bank and financial services company. Bioxodes’ lead candidate BIOX-101 targets a particularly deadly type of stroke: intracerebral hemorrhage (ICH). While responsible for only 15% of stroke cases, the disease claims 40% of all stroke-related deaths. Currently, no marketed treatment is available for these patients. That is why Bioxodes is using disruptive science to develop a therapeutic with breakthrough potential.